Adoptive therapy with autologous tumour-infiltrating T lymphocytes (TILs) represents a promising treatment for patients with metastatic melanoma. In phase II trials, where TILs are expanded, activated *ex vivo*, and then adoptively transferred into patients in combination with systemic high-dose interleukin-(IL)-2 following lymphodepletion, durable complete responses (CR) were observed in ∼20% of patients ([@bib35]). However, the administration of preparative chemotherapy and high-dose IL-2 is associated with significant toxicity and no pretreatment biomarkers of responsiveness useful for patient selection are currently available.

Several studies in humans and animal models suggest that the recruitment of activated T lymphocytes through CXCR3 and CCR5 chemokine ligands has a key role immune-mediated tissue destruction, including tumour rejection ([@bib48]; [@bib4]; [@bib15]; [@bib39]; [@bib17]). We observed that systemically administered IL-2 induces inflammation within tumours leading to production of lymphocyte chemoattractants including CXCR3 and CCR5 ligands ([@bib29]; [@bib28]; [@bib4]; [@bib49]). Indeed, the localisation of TILs within tumours is a necessary, although not sufficient, condition for tumour rejection ([@bib32]). Thus, we postulated that polymorphisms and/or expression of *CXCR3* and *CCR5* may quantitatively and/or qualitatively influence chemokine receptor expression, and therefore influence migration of TILs to tumours and their regression.

The *CCR5* polymorphism Δ32 consists of a 32-base deletion encoding a protein not expressed on the cell surface. Consequently, heterozygosity results in decreased and homozygosity absent receptor expression ([@bib18]; [@bib5]). A retrospective study reported decreased survival of patients with metastatic melanoma carrying the *CCR5*-Δ32 polymorphism treated with immunotherapy ([@bib43]). A common single nucleotide polymorphism (rs2280964) of *CXCR3* has been recently associated with variation in receptor expression, lymphocyte chemotactic activity, and risk of developing asthma ([@bib7]).

Here, in a prospective-retrospective hypothesis-driven analysis ([@bib37]), we investigated the role of *CXCR3* and *CCR5* expression and polymorphisms (i.e., rs2280964 for C*XCR3* and Δ32 for *CCR5*) by sequencing and profiling infused TILs from patients with metastatic melanoma undergoing adoptive therapy (*N*=142). Results were validated using flow cytometry (*N*=50). The role of *CXCR3*/*CCR5* ligand gene expression was assessed by profiling matched pretreatment tumour biopsies (*N*=113).

Materials and methods
=====================

Patient samples
---------------

Samples from 142 patients were available: 142 TILs and 113 paired pretreatment tumour biopsies for RNA extraction, and 141 TILs for DNA extraction. Fifty paired TIL samples were also analysed using flow cytometry. Tumour-infiltrating lymphocytes were frozen just before the infusion. Samples were collected during five consecutive trials at the Surgery Branch, National Cancer Institute ([@bib9]; [@bib35]; [@bib42]; <http://www.clinicaltrials.gov/ct2/show/NCT00513604?term=07C0176&rank=1>), codified as: TNMA, T200, T1200, TYT, and TCD8 ([Table 1](#tbl1){ref-type="table"}). All patients had progressive disease and had previously received standard or experimental regimens. Fifty percent of the patients (71 out of 142) achieved an objective response (OR), of which 25 (18%) experienced a durable CR and 46 (32%) a partial response (PR). Tumour biopsy samples included 24 CR (21%), 34 PR (30%) and 55 (49%) non-response (NR) samples.

Total body irradiation (TBI; 2 or 12 Gy) was administered in conjunction with chemotherapy in T200 and T1200 trials, respectively ([@bib35]). A day following lymphodepletion, TILs were infused into patients and high-dose IL-2 therapy was started. Protocols employed to generate TILs are described elsewhere ([@bib11]; [@bib41]; [@bib9]; [@bib35]). Before TIL administration, patients received a non-myeloablative lymphodepleting regimen consisting of cyclophosphamide at 60 mg kg^−1^ per day for 2 days and fludarabine at 25 mg m^−2^ per day for 5 days ([@bib9]; [@bib35]). A day following lymphodepletion, TILs were infused into patients and high-dose IL-2 therapy was started (720 000 IU kg^−1^ intravenously every 8 h to tolerance). Major inclusion criteria included minimum age of 18 years, measurable disease, good clinical performance and life expectancy greater than 3 months. Detailed study protocol information are available elsewhere (<http://www.clinicaltrials.gov/ct2/show/NCT00513604?term=07C0176&rank=1>), ([@bib9]; [@bib35]).

All patients signed an informed consent approved by the Institutional Review Board of the National Cancer Institute. Data for this analysis are updated as of 11 January 2012. Response (CR, PR, or NR) was rated according to the Response Evaluation Criteria in Solid Tumors guidelines 4 weeks following TIL administration and at regular intervals thereafter. A CR or PR was considered an OR and a PR or NR was considered a non-CR.

Sequencing
----------

DNA was successfully extracted from 141 TIL samples from frozen material (cell pellet) preserved at −80 °C. One sample was unavailable for DNA extraction. Total DNA was isolated with the Nucleic Acid Isolation System QuickGene-810 using the QuickGene DNA whole blood Mini Kit (Fujifilm, Tokyo, Japan).

Amplification PCR was carried out in a reaction mixture containing 4 *μ*l (40 ng) of DNA, 10 *μ*l of HotStar Taq Master Mix (Qiagen, Germantown, MD, USA), 1 *μ*l (10 pmol) of each of the following primers: forward 5′-CTGGCCATCTCTGACCTGTT-3′ and reverse 5′-CCCTGTGCCTCTTCTTCTCA-3′ for *CCR5* gene (Δ32 polymorphism) and forward 5′-CTCCCTACACTGAGGCTTGC-3′ and reverse 5′-AGCCATGGTCCTTGAGGTAA-3′ for *CXCR3* gene (rs2280964 polymorphisms). Primers were designed using the Primer3 software (<http://www.frodo.wi.mit.edu/>). For *CCR5* analysis, the reaction mixture was denatured at 95 °C for 10 min and cycled 35 times at 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 60 s, with final extension at 72 °C for 10 min. For CXCR3 analysis, the reaction mixture was denatured at 95 °C for 10 min and cycled 32 times at 94 °C for 45 s, 58 °C for 45 s, and 72 °C for 60 s, with the final extension at 72 °C for 10 min.

The PCR product was purified with Exosap-IT (USB Corporation, Cleveland, OH, USA) according to the manufacturer\'s protocol. PCR products were visualised on ultraviolet transilluminated, ethidium bromide 2% Agarose gel (Invitrogen, Carlsbad, CA, USA).

Sequencing reactions were performed using 3.5 *μ*l of purified DNA product, 2 *μ*l of Big Dye terminator (Big Dye Terminator v3.1 cycle sequencing reaction kit, Applied Biosystems, Foster City, CA, USA) and 4 pmol of forward primer. The following conditions were used: initial temperature of 96 °C for 60 s, followed by 30 cycles at 96 °C for 30 s, 50 °C for 30 s, and 60 °C for 4 min. Excess dye terminators were removed using DyeEx 96 Kit columns as per the manufacturer\'s instructions (Qiagen).

The Sanger sequencing was performed on an ABI Prism 3730 XL instrument (Applied Biosystems). Data were analysed using Sequencher software v.4.9 (Gene Codes Corporation, Ann Arbor, MI, USA).

Samples for gene expression and sequencing experiments were processed in parallel during the same time period.

Gene expression
---------------

Total RNA was isolated from 142 TILs (cryopreserved just before the infusion into the patients) and 113 snap frozen tumour samples used for TIL generation. Total RNA was extracted with the Qiagen miRNeasy Mini kit and its quality was tested with the Agilent Bioanalyzer 2000 (Agilent Technologies, Palo Alto, CA, USA). Three hundred nanograms of total RNA were used for RNA amplification according to the manufacturer\'s instructions (WT Expression Kit; Ambion, Austin, TX, USA). Amplified RNA was reverse transcribed into cDNAs followed by fragmentation. After hybridisation to the GeneChip Human Gene 1.0 ST Arrays, the chips were labelled with a WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA, USA) and scanned on a GeneChip Scanner 3000 7G (Affymetrix). Data were normalised using the Robust Multi-Chip Average method and Log~2~-transformed using Partek Genomics Suite 6.4 (Partek Inc., St Louis, MO, USA). Data analyses were based on the whole transcripts.

Flow cytometry
--------------

Flow cytometry was performed in 50 TIL samples (cryopreserved just before the infusion into the patients) to validate the accuracy of genomic data in predicting cell surface protein expression. Tumour-infiltrating lymphocytes were selected as follows: (a) all available CRs; (2) samples concomitantly under- or overexpressing *CXCR3* and *CCR5*; (3) *CCR5*-Δ32 homozygous samples; and (4) *CCR5-*Δ32 heterozygous samples included in the protein prediction model (PPM; described in the Results section). Because of the non-random sampling (selection bias), a correlation analysis between receptor expression and response was neither planned nor performed. Tumour-infiltrating lymphocyte samples included 18 CR (11 *CXCR3/CCR5* low and 7 *CXCR3/CCR5* high), 3 PR (*CXCR3/CCR5* high) and 29 NR (14 *CXCR3/CCR5* low and 15 *CXCR3/CCR5* high) cases. Ten *CCR5*-Δ32 heterozygous (six PR, two CR and two NR) and one *CCR5*-Δ32 homozygous samples were selected, including six samples that were reclassified as the low group according to the PPM. Tumour-infiltrating lymphocytes preserved in liquid nitrogen were thawed, washed, immediately stained and analysed. FITC-labelled anti-CCR5 and PE-labelled anti-CXCR3 antibodies were used for chemokine receptor expression analyses. 7AAD antibodies were used to identify dead cells allowing for gating and analysis of live cells only. Samples were also stained with the appropriate isotype controls. Cells were analysed on a FACSCalibur flow cytometer (Becton Dickinson & Co, San Jose, CA, USA). Thirty thousand events were acquired on the FACSCalibur from each of the TIL samples for analysis. Daily fluctuations of the FACSCalibur flow cytometer were controlled by using Sphero 8 peak Rainbow Calibration Particles (Becton Dickinson & Co) and specific fluorescencent signal were calculated on the live cells by normalising to the appropriate isotype control, as described elsewhere ([@bib33]). All of the antibodies were from Becton Dickinson & Co. Samples were stained according to the manufacturer\'s protocols.

Statistical analysis
--------------------

The difference of the overall outcome distribution (CR, PR, and NR) among *CXCR3* and *CCR5* polymorphism classes was assessed using the Kruskal--Wallis test that accounts for the ordered nature of the outcomes (i.e., degree of response: CR better than PR better than NR). The distribution of OR and CR between *CXCR3* and *CCR5* classes was then assessed by the *χ*^2^-test or Fisher\'s exact test, as appropriate (i.e., if any category has a cell count \<5). Odds ratios with their 95% CI were also reported, as appropriate. To minimise 'data overfitting biases\', statistical significance levels and confidence intervals are not reported for data-derived hypotheses. As for the *CXCR3* rs2280964 polymorphism, the four G carriers were not included in the genotype-response and genotype-transcript level correlation analysis. The associations between the expression of *CXCR3* and *CCR5* in TILs and clinical responses were first assessed individually by the Spearman rank correlation coefficient (*ρ*) tests, which account for the ordered nature of the outcomes. One sample was unavailable for genotyping. Logistic regression models were used to assess the joint association between the expression of *CXCR3* and *CCR5*, the *CCR5*-Δ32 polymorphism, and their interactions with the clinical outcome, defined as either CR or OR. The log likelihood ratio test to was used to compare the fit of two models, one of which (the null model) is a special case of the other (the alternative model). The test is based on the log likelihood ratio, which expresses how many times more likely the data are under one model than the other. The null distribution of log likelihood is generated by calculating the log likelihood for each permutation. The variables included in the model are defined as follows: *X1*, *X2*, *X3* are binary variables; *X1*=1 when Log~2~ gene expression value of *CCR5*\>median; *X1*=0 when Log~2~ gene expression value of *CCR5*⩽median; *X2*=1 when Log~2~ base gene expression value of *CXCR3*\>median; *X2*=0 when Log~2~ base gene expression value of *CXCR3*⩽median; *X3*=0 when *CCR5* polymorphism Δ32 is present; wild-type (WT)=1; Rx=treatment (TNMA, T200, T1200, TYT, and TCD8); Y: end point (CR or OR). During the model fitting, the sample with missing genotype data was omitted.

The gene expression model included *CXCR3* and *CCR5* expression and their interaction (model A). The gene expression/polymorphism model included *CXCR3* and *CCR5* expression, *CCR5*-Δ32 polymorphism, and their interaction (model B). Likelihood ratio tests were used to evaluate the statistical significance of effects in the models compared. The gene expression and the gene expression/polymorphism models were also controlled for treatment effect by including treatment variables in the two models (model C and model D, respectively).

In order to facilitate interpretation of the statistically significant interactions found in the logistic regression models, *CXCR3* and *CCR5* expression data were then dichotomised (low *vs* high) according to their respective median values and integrated with each other and with *CCR5*-Δ32 polymorphism data, resulting in a PPM.

Univariate associations between TIL and tumour *CXCR3* and *CCR5* expression and their polymorphisms were assessed by Student\'s *t*-test (*CCR5*-Δ32 polymorphism) after checking for normal distribution (the D′Agostino--Pearson normality test) or by the Spearman rank correlation coefficient (*ρ*) test (*CXCR3* rs2280964 polymorphism). Association between sex, age and clinical outcomes (CR or OR), as well as cluster enrichment analysis was assessed by the *χ*^2^- or Fisher exact test, as appropriate.

Correlation between flow cytometry and gene expression data was assessed by the Spearman rank correlation coefficient (*ρ*) test as flow cytometry data were not normally distributed.

The correlation matrix of tumour biopsy gene expression data was based on the Spearman rank correlation coefficient (*ρ*) test because not all the data were normally distributed. Hierarchical clustering was based on the Euclidean distances, and was performed with Partek Genomics Suite 6.4. Probability (*P*) values \<0.05 (two-sided) were considered to be statistically significant. All statistical tests were two sided. Analyses were performed with SPSS version 18.0 (SPSS, Chicago, IL, USA), Partek Genomics Suite 6.4 (Partek Inc., and R ([@bib3]).

Single subject *CXCR3* rs2280964 genotypes (HapMap and 1000 Genome Projects, CEU populations) were downloaded from ensembl (<http://www.useast.ensembl.org/index.html>).

Results
=======

Tumour-infiltrating lymphocyte sequencing
-----------------------------------------

Demographic characteristics of the study population are shown in [Table 1](#tbl1){ref-type="table"}. As for *CXCR3* (located on the X chromosome), no association was observed between response and rs2280964 genotype ([Table 2](#tbl2){ref-type="table"}). The frequencies of T allele were 0.24 and 0.30 in men and women, respectively. These frequencies are similar to those reported in individuals with European ancestry (T-allele frequency in men: 0.26 and 0.20, CEU HapMap, and CEU 1000 Genomes Project, respectively; T-allele frequency in women: 0.22 and 0.27, CEU HapMap, and CEU 1000 Genomes Project, respectively). Interestingly, we found four men (one CR, two PR, and one NR) carrying the G allele (electopherograms in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Although rs2280964 is annotated as bi-allelic (C/T) polymorphism in the dbSNP database (<http://www.ncbi.nlm.nih.gov/snp/?term=2280964>), HapMap project and genome-wide association studies (both array based) might miss the identification of tri-allelic variants ([@bib12]). In fact, array-based genotyping need the knowledge of a third allele being present for the assays design, otherwise the third allele cannot be detected without using appropriate imputation algorithms ([@bib19]). However, programs used to genotype the current phase 1 release of 1000 Genomes Projects (sequencing based) are unable to genotype sites with more than two alleles. (<http://www.1000genomes.org/faq/are-all-genotype-calls-current-release-vcf-files-bi-allelic>).

As for *CCR5*, the frequency of the Δ32 genotype is ∼20% in Caucasians ([@bib5]). Similarly, we found 26 patients (18.4%) carrying the Δ32 polymorphism (1 homozygous and 25 heterozygous). The difference in the overall distribution of the outcomes for the WT and Δ32 patients was borderline significant (*P=*0.058) when checked with the Kruskal--Wallis test that assumes a progressive enrichment of one genotype over the other in three ordered response classes (i.e., CR\>PR\>NR). Although the CR rate was similar between the two groups (24% *vs* 16%), 17 of 25 patients (68%) carrying the Δ32 polymorphism (including the homozygous patients) experienced an OR, whereas only 53 of 116 (46%) WT patients experienced an OR (odds ratio=2.53, CI=1.01--6.32, Δ32 *vs* WT patients, respectively, *P=*0.043, [Table 2](#tbl2){ref-type="table"}).

Tumour-infiltrating lymphocyte gene expression and integrated gene expression and sequencing analysis
-----------------------------------------------------------------------------------------------------

No differences in *CXCR3* and *CCR5* expression in TILs among the response classes was observed when data were compared by the Spearman rank correlation coefficient (*ρ*) test, which assumes a progressive change in gene expression in the three ordered response classes (i.e., CR\>PR\>NR or CR\<PR\<NR), having CR and PR samples the lowest and the highest transcript levels (*CXCR3* and *CCR5* gene expression data distribution is shown in [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

To evaluate the weight on response of the coordinate expression of *CXCR3* and *CCR5,* which have redundant functions, we utilised logistic regression analyses ([Table 3](#tbl3){ref-type="table"}). The gene expression model with interaction (full A model), included as predictor variables the expression of the two genes in TILs and the two-way interaction between the individual gene expressions. This model was significantly associated with CR (*P*=0.032) but not significantly associated with OR (*P*=0.15). The gene expression/polymorphism model with interaction (full B model) includes the variables of the full A model as well as an indicator variable for Δ32 polymorphism and the two-way and three way interaction of the *CCR5*-Δ32 polymorphism with the gene expression variables. By adding the DNA dimension (*CCR5*-Δ32 polymorphism), the model was significantly associated with both CR (*P*=0.0009) and OR (*P*=0.007). The gene expression/polymorphism model with interaction (full B model) performed significantly better than the gene expression model with interaction (full A model) for both CR (*P*=0.003) and OR (*P*=0.007). As we detected a significant difference in OR and CR rates across the cohorts (see demographic characteristics in [Table 1](#tbl1){ref-type="table"}), we also evaluated models containing a treatment group factor, as well as the other variables. With this adjustment (model C and D), the gene expression model with interaction (full C model) remained significantly associated with CR (*P*=0.002), and became also significantly associated with OR (*P*=0.010). The gene expression/polymorphism model with interaction (full D model) remained significantly associated with CR (*P*=0.0001) and with OR (*P=*0.003) and, again, was significantly better than the gene expression model with interaction for CR and OR (*P*=0.005 and *P*=0.036, respectively). A detailed description of the results of the logistic regression models, including intermediate models, is reported in [Supplementary Tables S1 and S2](#sup1){ref-type="supplementary-material"}. Despite the possible intrinsic data overfitting, the employment of logistic models, which assess all the combination among the variables analysed, reduce biases related to the selection of group comparisons. Overall, these models clearly (and consistently) show that the addition of new dimensions to data (e.g., combinatorial gene expression analysis and integration with genetic polymorphisms) can increase the chances to identify patients more probably to respond to treatment.

To understand the significant interactions identified by the logistic modelling, samples were grouped according to the expression of chemokine receptor genes. The *CXCR3-*low group was enriched in CR samples (CR rate: 25% *vs* 10%, odds ratio=3.11, *CXCR3* low *vs* high, respectively, [Figure 1A](#fig1){ref-type="fig"}). The *CCR5*-low group was also slightly enriched in CR samples (CR rate: 21% *vs* 14%, odds ratio=1.63, CCR5 low *vs* high, respectively). Similar OR rate was observed in *CXCR3*-low group (as compared with *CXCR3* high group), and in *CCR5*-low group (as compared with *CCR5-*high group, [Figure 1B](#fig1){ref-type="fig"}).

We then explored the coordinate underexpression of both transcripts. The samples with *CXCR3* and *CCR5* expression values below the median were grouped in the category *CXCR3/CCR5* low (*n*=41) and those with at least one above the median were grouped as *CXCR3/CCR5* high (*n*=101). Co-underexpression of both genes was strongly associated with achievement of CR: 32% of patients in the *CXCR3/CCR5*-low group achieved a CR compared with 12% in the *CXCR3/CCR5*-high group (odds ratio=3.44, [Figure 1A](#fig1){ref-type="fig"}). A similar trend was observed in the OR analysis ([Figure 1B](#fig1){ref-type="fig"}).

As the protein expression of CCR5 on TIL cell surface was expected to be reduced in *CCR5*-Δ32 patients (partially in heterozygous, complete in homozygous), we integrated this variable (i.e., *CCR5*-Δ32 polymorphism) with gene expression values to build a PPM. In the PPM (rational explained in detail in [Figure 2](#fig2){ref-type="fig"}), *CCR5*-Δ32 carriers with high *CCR5* transcript levels (*CCR5* high) were included in the CCR5-low (PPM) group and in the CXCR3/CCR5-low (PPM) group if *CXCR3* was low. By adding this dimension, the disproportion of CR and OR samples between the CXCR3/CCR5-low *vs* -high group (PPM) increased (CR rate: 36% *vs* 8%, odds ratio=6.16; OR rate 64% *vs* 43%, odds ratio=2.32, CXCR3/CCR5 low *vs* high (PPM), respectively).

No association was observed between expression of *CXCR3* or *CCR5* and the corresponding polymorphism in TILs or in tumour samples ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

Tumour-infiltrating lymphocyte flow cytometry
---------------------------------------------

We validated the correlation between transcript and protein level in 50 available TIL samples ([Figure 3](#fig3){ref-type="fig"}). All TIL samples displayed strong, although variable, expression of CXCR3. CCR5 expression was weaker. The fluorescence intensity curve of the two chemokine receptors assumed a skewed Gaussian distribution without the evidence of well-defined subpopulations. Protein expression of CXCR3 correlated with the expression of their respective transcripts ([Figure 3A](#fig3){ref-type="fig"}). *CCR5* transcript expression and CCR5 protein expression correlated in both WT and Δ32 samples ([Figure 3E and F](#fig3){ref-type="fig"}). *CCR5-*Δ32 strongly influenced the expression of CCR5 protein. The lower expression of CCR5 protein in *CCR5-*Δ32 in monocytes and T cells from *CCR5-*Δ32 carriers has been previously demonstrated ([@bib5]), but no data are available (to the best of our knowledge) on TILs. In fact, TILs used for adoptive therapy are cultured and expanded *in vitro* with consequent possible modulation of surface markers. We observed that the level of *CCR5* receptor in *CCR5-*Δ32 heterozygous samples expressing high levels of *CCR5* transcripts was approximately the half of that detected in *CCR5* WT samples ([Figure 3D](#fig3){ref-type="fig"}). No expression of CCR5 receptor on cell surface was observed (as expected) in the *CCR5*-Δ32 homozygous sample. Therefore, even if post-transcriptional changes could influence the expression of CCR5 receptor ([@bib36]), the presence of Δ32 polymorphism has a major role in lowering the expression of CCR5 protein in presence of high *CCR5* transcripts in TILs.

Despite the bias selection (see Materials and Methods section), it is noteworthy that only 1 out of 18 CR samples overexpressed both chemokine receptors ([Figure 4](#fig4){ref-type="fig"}). Thus, flow cytometry confirmed the PPM suggesting that estimates based on germ line and transcriptional data could be extended to the remaining samples for which TILs were no longer available.

Pretreatment tumour biopsy gene expression
------------------------------------------

We investigated the role of the coordinate intratumoral expression of CXCR3/CXCR3 ligand gene expression (i.e., *CXCL9, CXCL10*, and *CXCL11*) and CCR5/CCR5 ligands (i.e., *CCL3, CCL4*, and *CCL5*) in 113 available pretreatment tumour biopsies used for TIL generation.

*CXCL9, CXCL10, CXCL11* and *CCL5* were co-expressed ([Figure 5A](#fig5){ref-type="fig"}) and, when used for hierarchical clustering analysis based on mean-centered expression values ([Figure 5B](#fig5){ref-type="fig"}), segregated melanoma metastases into three main groups: cluster 1 included samples with low CXCR3 and CCR5 ligand gene expression; cluster 2 and cluster 3 with intermediate and high expression, respectively. Cluster 1 was disproportionately enriched with samples from NR patients (OR rate: 38%, *P=*0.030) and cluster 3 with samples from OR patients (OR rate: 65%, *P=*0.031), whereas cluster 2 included an intermediate proportion of OR samples (52%), suggesting an association between expression of *CXCL9, CXCL10, CXCL11* and *CCL5* and immune responsiveness. CXCL9, CXCL10, CXCL11 and CCL5 are the classical interferon inducible chemokines and are coordinately regulated by STAT1 signalling ([@bib6]; [@bib34]). No correlation with CR or OR was observed when samples were clustered according to the other markers (i.e., *CCL3, CCL4, CXCR3,* and *CCR5,* [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Activated cytotoxic and helper-1 T cells express CXCR3 and CCR5 on cell surface ([@bib14]). The intratumoral overexpression of *CXCR3* and/or *CCR5* ligand genes in primary tumours has been correlated with high density of T cells and reduced risk of relapse or death in the lung (*CCL5;* [@bib25]), melanoma (*CCL5, CXCL9,* and *CXCL10*), ovarian, (*CXCL9* and *CCL5;* [@bib50]; [@bib21]) colorectal (*CCL5, CXCL9,* and *CXCL10;* [@bib24]; [@bib40]), and breast cancer (*CCL5, CXCL9,* and *CXCL10;* [@bib2]; [@bib8]). Consistently, [@bib23] recently reported a prolonged survival in metastatic melanoma patients bearing tumours overexpressing *CCL3, CCL4, CCL5, CXCL9, CXCL10*, and *CXCL11* (Messina *et al*, 2012). In addition, these chemokine genes have been associated with a higher likelihood to respond to ipilimumab (*CCL4, CCL5, CXCL9, CXCL10*, and *CXCL11;* [@bib20]) and MAGE-A3 vaccination (*CXCL9, CXCL10* and *CCL5;* [@bib44]) ([@bib45]).

Testing pretreatment biopsies from 113 melanoma patients undergoing adoptive therapy, we observed that the coordinated activation of the classical interferon inducible chemokine *CXCL9, CXCL10, CXCL11* and *CCL5* ([@bib34]) progressively increases the probability of response to adoptive therapy. *CXCL9, CXCL10* and *CCL5* represent the chemokines most frequently associated with both favourable prognostic and predictive role ([@bib16]). We proposed that these chemokines identify a specific cancer immune phenotype ('Th1, interferon-driven phenotype\') associated with better prognosis and responsiveness to immune manipulations ([@bib1]; [@bib38]; [@bib16]; [@bib26]).

We hypothesised that adoptively transferred TILs should be most likely to be effective when expressing high levels of the corresponding chemokine receptors. [@bib43] reported that metastatic melanoma patients who carried one or two *CCR5*-Δ32 alleles suffer worse survival following immunotherapy or immunochemotherapy. The results from the 142 TILs were in apparent contradiction with this hypothesis. The CXCR3/CCR5 expression status was opposite than predicted. *CCR5-*Δ32 polymorphism, and *CCR5* and *CXCR3* transcript underexpression in TILs were associated with downregulation of the corresponding receptors and higher likelihood (OR rate) and degree (CR rate) of response. The association with achievement of a CR is intriguing and particularly relevant as CR patients treated with adoptive therapy usually experience a extremely durable remission (up to 100% of overall survival at 3 years ([@bib35])). The strength of the association with response progressively increased as *CCR5* and *CXCR3* expression data were combined and were integrated with *CCR5* sequencing data, as indicated by the log likelihood test for models.

These counterintuitive and surprising results could be explained by the dynamics of TIL migration to the tumour in relation to concomitant IL-2 administration. Localisation of TILs to the tumour site is necessary for their antitumour activity ([@bib32]). However, soon (2 h) after high-dose IL-2 administration, the infused TILs rapidly disappear from the circulation. They do not localise to tumour tissue and rather migrate to normal liver, lung, and spleen ([@bib13]). Migration to the tumour begins 24 or 48 h after IL-2 administration and increases over time during the following days ([@bib13]). However, concentrations of CCR5 and CXCR3 ligands (e.g., CCL3, CCL4, CXCL9, CXCL10 and CXCL11) increase immediately after IL-2 administration ([@bib30]). Our previous genomic and proteomic studies suggest that IL-2 seems to exert its effect on the tumour site indirectly by inducing monocyte activation, followed by a delayed, dose-dependent release of chemoattractants such as CXCR3 and CCR5 ligands that recruit TILs only in the later stages of treatment ([@bib29]; [@bib47]; [@bib30]; [@bib49]). In fact, administration of IL-2 is followed by a rapid clearance of peripheral mononuclear cells, without any evidence of their migration to tumour metastases at early time points ([@bib29]), consistently with results from adoptive therapy studies ([@bib32]). Several richly perfused organs including the lung and liver, populated with IL-2-receptor carrying cells, are probably the primary target of systemic IL-2 administration, and it is there where the inflammatory cytokine storm is probably initiated leading, among others, to the production of massive quantities of CXCR3 and/or CCR5 ligands. A significant association was reported with increased persistence of TILs in the circulation 1 month following treatment and likelihood of clinical response ([@bib10]; [@bib35]). It is tempting to hypothesise that a low expression of chemokine receptors by TILs in the acute phases of treatment might prevent their sequestration by extratumoral tissues and paradoxically allow their subsequent localisation to the tumour when the cytokine storm has subsided and the tumour remains the only tissue maintaining expression of chemokines. This hypothesis would be consistent with the favourable predictive weight that higher expression of *CXCL9, CXCL10, CXCL11,* and *CCL5* in steady state conditions confers. The enhancement of the expression of these chemokines in tumour/tumour microenvironment could identify novel strategies for the improvement of current immunotherapies ([@bib27]; [@bib31]).

These ligands could modulate the tumour microenvironment in other ways, independently of the recruitment of T cells. CCR5 blockade, for example, has been demonstrated to enhance proliferation of xenografts from breast cancer cells bearing WT p53, and the presence of Δ32 polymorphism has been associated with higher risk of relapse in breast cancer patients with p53 WT tumours ([@bib22]). Thus, the aforementioned observation of [@bib43] only apparently clashes with our findings. As response rate was not assessed in that study, the Δ32 polymorphism mutation may have enhanced tumour growth through a direct effect on tumour biology ([@bib22]), resulting in the observed poor survival in these patients ([@bib43]). As in our study the presence of *CCR5-*Δ32 mutation was not associated with worse response (and rather, when considered as single parameter, it was marginally associated with better OR, *P*=0.043), it is likely that the direct modulation of CCR5 in cancer tumour cells has a little (if any) impact on the clinical outcome of patients undergoing adoptive therapy.

However, it is possible that aside from the adoptive transfer model, when activated CXCR3+/CCR5+ TILs are infused in combination with high-dose IL-2, during other treatments (e.g., combination of immunochemotherapy ([@bib43])), the proportional induction of the CXCR3 and CCR5 ligands following treatment is not as unbalanced as it is in our study.

Although we stress that our findings must be prospectively validated, the significance of our observation is supported by the fact that it does not come from a merely retrospective investigation. Retrospective investigations performed on archived specimens are often conducted independent of a specified protocol and are unfocused, with numerous patient subsets and end points ([@bib37]). Our prospective-retrospective ([@bib37]) investigation was rather designed to study specimens collected during prospective trials and specifically stored to preserve DNAs, mRNAs and proteins in order to perform the dedicated assays.

Animal models can provide important mechanistic insights into human diseases. Studies in mouse models employing adoptively transferred lymphocytes have emphasised a key role of the upregulation of CCR5 in TILs in mediating tumour rejection ([@bib17]). Our present study, however, fails to demonstrate that the downregulation of CCR5 in TIL is a detrimental factor in this setting in humans.

However, in view of the intrinsic limitations of the investigation (e.g., the possible data overfitting because of the use of regression models), our results should be considered exploratory and need to be validated by integrated quantitative PCR, sequencing, and flow cytometric analyses in an independent cohort of patients.

Considering the complexity of tumour--host interactions, we believe that only a prospective clinical translation study employing serial biopsies (i.e., pre- and post treatment) in different tissues and specifically designed to asses T-cell tumour trafficking in humans can conclusively confirm the hypotheses generated by our present report.

In conclusion, our study identified candidate biomarkers of immune responsiveness in this setting by applying a combinatorial multifactorial approach. In fact, none of the individual parameters assessed had predictive value alone, but the coordinated analysis of the two molecules corrected for the predicted function according to the genetic polymorphism yielded strong predictive value. This point proposes a paradigm shift for the identification of clinically relevant biomarkers in complex biological problems. The optimisation of this approach in genomic-scale models represents a future challenge ([@bib46]).
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![**Effect of *CXCR3*/*CCR5* expression status of tumor-infiltrating lymphocytes (TILs) on complete response (**A**) and objective response (**B**).** Odds ratios are represented*. CCR5*-Δ32 (DNA): presence of Δ32 polymorphism; *CCR5*-Δ32 low (PPM): CCR5 low according to the PPM (*CCR5* below the median value according to the gene expression data or presence of *CCR5*-Δ32 polymorphism); *CCR5* low (mRNA): *CCR5* below the median value according to the gene expression data; *CXCR3* low (RNA): *CXCR3* below the median value according to the gene expression data; *CXCR3/CCR5* low (mRNA): *CXCR3* and *CCR5* below the median value according to the gene expression data; CXCR3/CCR5 low (PPM): *CXCR3* and *CCR5* below the median value according to the gene expression data or *CXCR3* low and *CCR5* high in presence of *CCR5-*Δ32 polymorphism. *P-*values are from *χ*^2^-test. Abbreviations: CI=confidence interval; CR=complete response; non-CR=PR+NR; OR=objective response (CR+PR); PPM=protein prediction model; PR=partial response; WT=wild-type.](bjc2013557f1){#fig1}

![**Protein prediction model.** In wild-type subjects (**A**) we assume that high levels of *CCR5* transcript are associated with high expression of *CCR5* on cell surface. However, because Δ32 polymorphism encodes a protein not expressed on the cell surface (**B**), *CCR5*-Δ32 carriers were expected to have a low receptor expression (decreased in heterozygous individuals and absent in homozygous individuals) despite the high transcript expression.](bjc2013557f2){#fig2}

![**Correlation between *CXCR3/CCR5* transcript and protein expression in tumour-infiltrating lymphocytes (TILs).** (**A**) Scatter plot representing the Spearman correlations between *CXCR3* transcript (Log~2~ intensity, *x* axis) and protein expression (Fsp, *y* axis). (**B**) Overlaid histograms representing three representative CR samples with low level of *CXCR3* transcript and receptor expression, and three NR samples with high level of *CXCR3* transcript and receptor expression (according to the median value). Each sample is stained with CXCR3-PE (light blue graph) or with the corresponding IC (red graph). (**C**) Box plots showing the comparisons between samples with different *CCR5* expression values (low and high according to the median value based on gene expression) and *CCR5*-Δ32 status (*x* axes): (**D**) Overlaid histograms exhibiting three representative CR samples with low level of *CCR5* transcript and receptor expression and three NR samples with high level of CCR5 receptor expression (according to the median value). CR panel includes two *CCR5* wild-type samples and one *CCR5*-Δ32 heterozygous sample. NR panel includes three *CCR5* wild-type samples. Each sample is stained with CCR5-FITC (light blue graph) or with the corresponding IC (red graph). (**E**, **F**) Scatter plots representing the Spearman correlations between CCR5 transcript (Log~2~ intensity, *x* axis) and protein expression (Fsp, *y* axis) within all the samples (**E**) or within the *CCR5*-Δ32 heterozygous samples (**F**). Box plots: the top and the bottom edge of the tinted boxes show the values of the upper and lower quartiles, respectively. The top and the end of the whiskers represent the maximum and the minimum values excluding the outliers (which are plotted as individual dots). The horizontal lines indicate the median value. Specific fluorescent signal (Fsp) was calculated on live cells (7AAD negative) by normalising to the respective isotype control. Abbreviations: Δ32 Het mRNA low=*CCR5*-Δ32 heterozygous and *CCR5* mRNA low; Δ32 Het mRNA high=*CCR5*-Δ32 heterozygous and *CCR5* mRNA high; Δ32 Hom=*CCR5*-Δ32 homozygous; CR=complete response; PR=partial response; WT mRNA low=*CCR5* wild-type and *CCR5* mRNA low; WT mRNA high=*CCR5* wild-type and *CCR5* mRNA low; *y* axis represents CCR5-specific fluorescence signal (Fsp). *P*-values are from the Spearman rank correlation coefficient (*ρ*) test.](bjc2013557f3){#fig3}

![**Flow cytometry analysis of CXCR3 and CCR5 receptor expression by tumour-infiltrating lymphocytes (TILs).** (**A**) Scatter plot of CXCR3 and CCR5 protein expression on cells surface. *x* axis: CCR5-specific fluorescent signal (Fsp); *y* axis: CXCR3-specific fluorescent signal (Fsp). Vertical and horizontal dotted lines represent the median values of the *x* and *y* axes, respectively. CR samples are represented with red dots, PR samples with green dots and NR samples with blue dots. The short grey arrows indicate *CCR5*-Δ32 heterozygous sample and the long grey arrow indicates the *CCR5*-Δ32 homozygous sample. (**B**) Flow cytometry scatter plots of three representative CR samples with low levels of *CXCR3* and *CCR5* transcript and receptor expression and three NR samples with high level of *CXCR3* and *CCR5* transcript and receptor expression (according to the median value) are represented. CR panel includes two *CCR5* wild-type samples and one *CCR5*-Δ32 heterozygous sample. NR panel includes three *CCR5* wild-type samples. Each sample was stained with CXCR3-PE and CCR5-FITC (light blue dots) or with the corresponding IC (red dots). *CXCR3* and *CCR5* gene expression status and *CCR5* polymorphism is indicated for each sample. Specific fluorescent signal was calculated on live cells (7AAD negative) by normalising to the respective IC. Abbreviations: CR=complete response; IC=isotype control; OR=objective response (CR+PR); PR=partial response.](bjc2013557f4){#fig4}

![***CXCR3*/*CCR5* ligands gene expression in pretreatment biopsies.** (**A**) Hierarchical clustering of gene--gene correlation from 113 pretreatment tumours. The Spearman rank correlation coefficient (*ρ*) was calculated between combination of *CXCR3, CCR5*, CXCR3 ligands (*CXCL9, CXCL10,* and *CXCL11)* and CCR5 ligands (*CCL3, CCL4,* and *CCL5*). *CXCL9, CXCL10, CXCL11* and *CCL5* clustered together and were selected for hierarchical clustering analysis based on the mean-centered gene expression values (**B**). Patients with clinical complete responses (CR) are shown in red, patients with partial remission (PR) are shown in green and non-responders (NR) are shown in blue. Abbreviations: non-CR=PR+NR; OR=objective response (CR+PR). *P-*values are from the *χ*^2^-test.](bjc2013557f5){#fig5}

###### Patient and treatment characteristics

                                                       **CR**    **NR**    **NR**    **All,** ***n*****=142** ***n*** **(%)**   **Objective response (OR** ***vs*** **NR)**\*   **Complete response (CR** ***vs*** **non-CR)**\*
  ----------------------------------------- --------- --------- --------- --------- ------------------------------------------ ----------------------------------------------- --------------------------------------------------
  Male                                       *n* (%)   15 (17)   29 (33)   45 (51)                   89 (63)                                  1.06 (0.54--2.10)                                1.15 (0.47--2.78)
  Female                                     *n* (%)   10 (19)   17 (32)   26 (49)                   53 (37)                                  ***P*****-value**                                ***P*****-value**
                                                                                                                                                    0.86                                              0.76
  **Age (median: 46; range: 18**--**64)**                                                   **Age** ***P*****-value**                     **Age** ***P*****-value**            
  16--30                                     *n* (%)   3 (20)    3 (20)    9 (60)                    15 (11)                                        0.43                                              0.50
  31--45                                     *n* (%)   9 (18)    17 (33)   25 (49)                   51 (36)                                                                                            
  46--60                                     *n* (%)   13 (20)   23 (35)   30 (46)                   66 (47)                                                                                            
  61--75                                     *n* (%)    0 (0)    3 (30)    7 (70)                     10 (7)                                                                                            
  **Treatment**                                                                                                                        **Treatment** ***P*****-value**                  **Treatment** ***P*****-value**
  TNMA                                       *n* (%)   5 (13)    13 (33)   21 (54)                   39 (28)                                        0.015                                            0.017
  T200                                       *n* (%)   5 (21)    8 (33)    11 (46)                   24 (17)                                                                                            
  T1200                                      *n* (%)   10 (40)   8 (32)    7 (28)                    25 (18)                                                                                            
  TYT                                        *n* (%)    2 (8)    4 (16)    19 (76)                   25 (18)                                                                                            
  TCD8                                       *n* (%)   3 (10)    13 (45)   13 (45)                   29 (20)                                                                                            

Abbreviations: CI=confidence interval; CR=complete response; NR=no response; Non-CR=PR+NR; OR=objective response (CR+PR); PR=partial response; T200=2 Gy total body irradiation protocol; T1200=12 Gy total body irradiation protocol; TCD8=young TIL CD8-enriched protocol; TNMA=no total body irradiation protocol; TYT=young TIL protocol.

\**P-*values are from the *χ*^2^-test or the Fisher\'s exact test, as appropriate.

###### Correlation between *CXCR3 and CCR5* polymorphisms and outcome

  ***CXCR3*** **rs2280964**              **CR**                  **PR**                 **NR**    **All,** ***n*****=141** ***n*** **(%)**   **Response**[a](#t2-fn3){ref-type="fn"} **(CR\>PR\>NR)**   **Objective response**[b](#t2-fn4){ref-type="fn"}**(OR** ***vs*** **NR)**   **Complete response**[b](#t2-fn4){ref-type="fn"}**(CR** ***vs*** **non-CR)**
  --------------------------- --------- --------- ------------------------------------ --------- ------------------------------------------ ---------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------
  All                          *n* (%)   15 (17)                26 (30)                 46 (53)                   87 (62)                                                                                                         All=1.28 (0.54--3.01)                                                        All=0.83 (0.26--2.67)
  Male                         *n* (%)   9 (14)                 21 (33)                 33 (52)                   63 (45)                                                                                                       Female=1.26 (0.43--3.70)                                                      Female=0.64 (0.16--2.58)
  Female                       *n* (%)   6 (25)                  5 (21)                 13 (54)                   24 (17)                                       ***P-*****value**                                                   ***P-*****value**                                                            ***P-*****value**
                                                                                                                                                                     All=0.75                                                           All=0.58                                                                      All=0.75
                                                                                                                                                                   Female=0.94                                                         Female=0.68                                                                  Female=0.52
  **CT**                                                                                                                                                    **C+ C/T** ***vs*** **T**                               **C+ C/T** ***vs*** **T** **Odds ratio (95% CI)**                             **C+C/T** ***vs*** **T** **Odds ratio (95% CI)**
  All (female)                 *n* (%)   4 (15)                 10 (39)                 12 (46)                   26 (18)                                                                                                         All=0.95 (0.39--2.29)                                                        All=0.77 (0.26--2.31)
                                                                                                                                                                                                                                 Male=1.00 (0.37--2.27)                                                        Male=0.53 (0.16--1.82)
                                                                                                                                                                                                                                Female=0.50 (0.04--5.87)                                                     Female=1.81 (0.08--37.93)
  **T (TT or T/-)**                                                                                                                                             ***P*****-value**                                                   ***P-*****value**                                                            ***P*****-value**
  All                          *n* (%)   5 (21)                  7 (29)                 12 (50)                   24 (17)                                            All=0.80                                                           All=0.91                                                                      All=0.77
                                                                                                                                                                    Male=0.73                                                           Male=1.00                                                                    Male=0.32
                                                                                                                                                                   Female=0.92                                                         Female=1.00                                                                  Female=1.00
  Male                         *n* (%)   5 (24)                  5 (24)                 11 (52)                   21 (15)                                                                                                       **C** ***vs*** **T+T/C**                                                      **C** ***vs*** **T+T/C**
  Female                       *n* (%)    0 (0)                  2 (67)                 1 (33)                     3 (2)                                     **C** ***vs*** **T+T/C**                                            **Odds ratio (95% CI)**                                                      **Odds ratio (95% CI)**
                                                                                                                                                                                                                                  All=0.82 (0.41--1.65)                                                        All=0.95 (0.38--2.36)
                                                                                                                                                                                                                                 Male=1.00 (0.37--2.69)                                                        Male=0.53 (0.16--1.82)
                                                                                                                                                                                                                                Female=0.69 (0.23--2.04)                                                      Female=2.08 (0.51--8.47)
                                                                                                                                                                ***P-*****value**                                                   ***P-*****value**                                                            ***P-*****value**
                                                                                                                                                                     All=0.64                                                           All=0.59                                                                      All=1.00
                                                                                                                                                                    Male=0.73                                                           Male=1.00                                                                    Male=0.32
                                                                                                                                                                   Female=0.90                                                         Female=0.49                                                                  Female=0.48
  ***CCR5-***Δ***32***                   **CR**                  **PR**                 **NR**    **All,** ***n*****=141** ***n*** **(%)**                  **Response (CR\>PR\>NR)**                                  **Objective response (OR** ***vs*** **NR)**                                 **Complete response (CR** ***vs*** **non-CR)**
  Δ**32**                                                                                                                                                                                                            Δ**32** ***vs*** **WT** **Odds ratio (95% CI)**                              Δ**32** ***vs*** **WT** **Odds ratio (95% CI)**
  All                          *n* (%)   6 (24)    11[c](#t2-fn5){ref-type="fn"} (44)   8 (32)                    25 (18)                                                                                                           2.53 (1.01--6.32)                                                            1.61 (0.57--4.57)
  **WT**                                                                                                                                                        ***P-*****value**                                                   ***P-*****value**                                                            ***P-*****value**
  All                          *n* (%)   19 (16)                34 (29)                 63 (54)                   116 (82)                                            0.058                                                               0.043                                                                         0.37

Abbreviations: CI=confidence interval; CR=complete response; Non-CR=PR+NR; NR=no response; OR=objective response (CR+PR); PR=partial response; WT=wild-type.

One sample (PR) was not available for genotyping. As the *CXCR3* gene is located on the X chromosome, the association between *CXCR3* rs2280964 genotype and response was also separately evaluated in men and women. The four (men) patients carrying rs2280964 G allele (one CR, two PR, one NR) were not included in the correlative analysis.

*P-*values are from the Kruskall--Wallis test.

*P-*values are from the *χ*^2^-test or Fisher\'s exact test, as appropriate.

Included one patient homozygous for Δ32 polymorphism.

###### Association between TIL *CXCR3*, *CCR5* expression, *CCR5*-Δ32 polymorphism, and their interaction, with clinical outcome

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ------------------------------------------------------ -------
  **Model A (gene expression model): expression of** ***CXCR3*** **and** ***CCR5*****, and their interactions**                                                                                                                                                                         
  **Full model definition**                                                                                                                                                               **Association with clinical outcome**                                                         
                                                                                                                                                                                                     **Comparator**               **Outcome** ***P-*value**[a](#t3-fn1){ref-type="fn"}  
  Full model A                                                                                                                                                                                                                                             CR                           OR
  Y∼u+x1+x2+x1x2                                                                                                                                                                                           Y∼u                                           0.032                          0.15
  **Model B (gene expression/polymorphism model): expression of** ***CXCR3*** **and** ***CCR5*****, and** ***CCR5*****-**Δ**32 polymorphism**                                                                                                                                           
  **Full model definition**                                                                                                                                                               **Association with clinical outcome**                                                         
                                                                                                                                                                                                     **Comparator**               **Outcome** ***P-*value**[a](#t3-fn1){ref-type="fn"}  
  Full model B                                                                                                                                                                                                                                             CR                           OR
  Y∼u+x1+x2+x3+x1x2+x1x3+x2x3+x1x2x3                                                                                                                                                                       Y∼u                                           0.0009                         0.007
                                                                                                                                                                                                      Full model A                                       0.003                          0.007
  **Model C (gene expression and treatment model): treatment, expression of** ***CCR5*****and** ***CXCR3*****, and their interactions**                                                                                                                                                 
  **Full model definition**                                                                                                                                                               **Association with clinical outcome**                                                         
                                                                                                                                                                                                     **Comparator**               **Outcome** ***P-*value**[a](#t3-fn1){ref-type="fn"}  
  Full model C                                                                                                                                                                                                                                             CR                           OR
  Y∼u+Rx+x1+x2+x1x2                                                                                                                                                                                      Y∼u+Rx                                          0.002                          0.010
  **Model D (gene expression/polymorphism and treatment model): treatment, expression of** ***CXCR3*** **and** ***CCR5***, ***CCR5*****-**Δ**32 polymorphism, and their interactions**                                                                                                  
  **Full model definition**                                                                                                                                                               **Association with clinical outcome**                                                         
                                                                                                                                                                                                     **Comparator**               **Outcome** ***P-*value**[a](#t3-fn1){ref-type="fn"}  
  Full model D                                                                                                                                                                                                                                             CR                           OR
  Y∼u+Rx+x1+x2+x3+x1x2+x1x3+x2x3+x1x2x3                                                                                                                                                                  Y∼u+Rx                                          0.0001                         0.003
                                                                                                                                                                                                      Full Model C                                       0.005                          0.036
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ------------------------------------------------------ -------

Abbreviations: CR=complete response; OR=overall response; Rx=treatment (TNMA, T200, T1200, TYT, and TCD8); TIL=tumour-infiltrating lymphocyte; Y=end point (CR or OR); Y∼u=null model; X1=expression of *CCR5*; X2=expression of *CXCR3*; X3=*CCR5*-Δ32 polymorphism.

The log likelihood ratio test to was used to compare the fit of two models, one of which (the null model) is a special case of the other (the alternative model). The test is based on the log likelihood ratio, which expresses how many times more likely the data are under one model than the other. During the model fitting, the sample with missing genotype data was omitted.
